Among them, 66.7% were females, 19.4% were current or former smokers; all their major lesion(s) with resection or biopsy were adenocarcinomas, of them 88.9% were stage I (or earlier), 27.8% were adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA), and 52.8% were EGFR mutation-positive (Fig. 2b). Here, EGFR is linked to androgen insensitivity syndrome.